Announcements Trials

Browse Landscape

Phase

Phase 2 9 Phase 1/2 4 Phase 1 4 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 22 Genitourinary 11 Endocrine 8 NET 7 Gastrointestinal 6 CNS 3 Tumor-Agnostic 1 Other hematologic neoplasm 1 Lymphoid 1 Dermatologic 1

Conditions

Skin Neoplasms 1

Interventions

Dacarbazine 27 Nivolumab 26 pembrolizumab 22 Ipilimumab 20 3-ingenyl angelate 11 Interferon-alpha 10 Imiquimod 10 Temozolomide 9 trametinib 8 Vemurafenib 8 Photochemotherapy 8 Aminolevulinic Acid 8 methyl 5-aminolevulinate 7 dabrafenib 7 cemiplimab 7 aldesleukin 7 Introns 7 Surgical Procedures, Operative 6 Radiotherapy 6 Interferon alpha-2 6 Fluorouracil 6 Paclitaxel 5 Melphalan 5 Interleukin-2 5 Cisplatin 5 Chemotherapy, Adjuvant 5 talimogene laherparepvec 4 binimetinib 4 Specimen Handling 4 Opdualag 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Everolimus × Dermatologic × Clear all

NCT00799188 2025-12-19

CERTICOEUR

Hospices Civils de Lyon

Phase 3 Completed

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡